ID   TRPA1_RAT               Reviewed;        1125 AA.
AC   Q6RI86; F1LRH9;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   24-JUL-2024, sequence version 2.
DT   02-OCT-2024, entry version 125.
DE   RecName: Full=Transient receptor potential cation channel subfamily A member 1 {ECO:0000312|RGD:1303284};
DE   AltName: Full=Ankyrin-like with transmembrane domains protein 1 {ECO:0000312|RGD:1303284};
DE   AltName: Full=Wasabi receptor {ECO:0000250|UniProtKB:O75762};
GN   Name=Trpa1 {ECO:0000312|RGD:1303284};
GN   Synonyms=Anktm1 {ECO:0000303|PubMed:14712238};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY
RP   REGULATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Trigeminal ganglion;
RX   PubMed=14712238; DOI=10.1038/nature02282;
RA   Jordt S.-E., Bautista D.M., Chuang H.-H., McKemy D.D., Zygmunt P.M.,
RA   Hoegestaett E.D., Meng I.D., Julius D.;
RT   "Mustard oils and cannabinoids excite sensory nerve fibres through the TRP
RT   channel ANKTM1.";
RL   Nature 427:260-265(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3]
RP   TISSUE SPECIFICITY.
RX   PubMed=12654248; DOI=10.1016/s0092-8674(03)00158-2;
RA   Story G.M., Peier A.M., Reeve A.J., Eid S.R., Mosbacher J., Hricik T.R.,
RA   Earley T.J., Hergarden A.C., Anderson D.A., Hwang S.W., McIntyre P.,
RA   Jegla T., Bevan S., Patapoutian A.;
RT   "ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated
RT   by cold temperatures.";
RL   Cell 112:819-829(2003).
RN   [4]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   ASP-918.
RX   PubMed=18775987; DOI=10.1074/jbc.m803568200;
RA   Wang Y.Y., Chang R.B., Waters H.N., McKemy D.D., Liman E.R.;
RT   "The nociceptor ion channel TRPA1 is potentiated and inactivated by
RT   permeating calcium ions.";
RL   J. Biol. Chem. 283:32691-32703(2008).
RN   [5]
RP   ACTIVITY REGULATION.
RX   PubMed=21402443; DOI=10.1016/j.pain.2011.01.049;
RA   Chen J., Joshi S.K., DiDomenico S., Perner R.J., Mikusa J.P., Gauvin D.M.,
RA   Segreti J.A., Han P., Zhang X.F., Niforatos W., Bianchi B.R., Baker S.J.,
RA   Zhong C., Simler G.H., McDonald H.A., Schmidt R.G., McGaraughty S.P.,
RA   Chu K.L., Faltynek C.R., Kort M.E., Reilly R.M., Kym P.R.;
RT   "Selective blockade of TRPA1 channel attenuates pathological pain without
RT   altering noxious cold sensation or body temperature regulation.";
RL   Pain 152:1165-1172(2011).
CC   -!- FUNCTION: Ligand-activated Ca(2+)-permeable, nonselective cation
CC       channel (PubMed:14712238, PubMed:18775987). Involved in pain detection
CC       and possibly also in cold perception, oxygen concentration perception,
CC       cough, itch, and inner ear function (By similarity). Has a relatively
CC       high Ca(2+) selectivity, with a preference for divalent over monovalent
CC       cations (Ca(2+) > Ba(2+) > Mg(2+) > NH4(+) > Li(+) > K(+)), the influx
CC       of cation into the cytoplasm, leads to membrane depolarization. Has a
CC       central role in the pain response to endogenous inflammatory mediators,
CC       such as bradykinin and to a diverse array of irritants. Activated by a
CC       large variety of structurally unrelated electrophilic and non-
CC       electrophilic chemical compounds, such as allylthiocyanate (AITC) from
CC       mustard oil or wasabi, cinnamaldehyde, diallyl disulfide (DADS) from
CC       garlic, and acrolein, an environmental irritant. Electrophilic ligands
CC       activate TRPA1 by interacting with critical N-terminal Cys residues in
CC       a covalent manner. Non-electrophile agonists bind at distinct sites in
CC       the transmembrane domain to promote channel activation. Acts also as an
CC       ionotropic cannabinoid receptor by being activated by delta(9)-
CC       tetrahydrocannabinol (THC), the psychoactive component of marijuana.
CC       May be a component for the mechanosensitive transduction channel of
CC       hair cells in inner ear, thereby participating in the perception of
CC       sounds (By similarity). {ECO:0000250|UniProtKB:O75762,
CC       ECO:0000250|UniProtKB:Q8BLA8, ECO:0000269|PubMed:14712238,
CC       ECO:0000269|PubMed:18775987}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671,
CC         ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:14712238,
CC         ECO:0000269|PubMed:18775987};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827,
CC         ChEBI:CHEBI:18420; Evidence={ECO:0000250|UniProtKB:O75762};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Na(+)(in) = Na(+)(out); Xref=Rhea:RHEA:34963,
CC         ChEBI:CHEBI:29101; Evidence={ECO:0000250|UniProtKB:O75762};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(in) = K(+)(out); Xref=Rhea:RHEA:29463, ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000250|UniProtKB:O75762};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351,
CC         ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:O75762};
CC   -!- ACTIVITY REGULATION: Electrophilic ligands activate the channel by
CC       covalent modification of intracellular cysteines; Cys-622 plays a key
CC       role in covalent binding of electrophiles (By similarity).
CC       Extracellular Ca(2+) both potentiates and inactivates TRPA1; a rapid
CC       potentiation follows by slow desensitization (PubMed:18775987).
CC       Activated by increase in intracellular Ca(2+) concentration (By
CC       similarity). Inhibited by ruthenium red, a potent blocker of TRPV
CC       channels and selectively by A-967079 (PubMed:14712238,
CC       PubMed:21402443). Activated by benzyl isothiocyanate (BITC),
CC       iodoacetamide, sulfhydryl reactive agent MTSEA, N-methyl maleimide
CC       (NMM), N-ethylmaleimide (NEM), and 2-aminoethyldiphenylborinate (2-
CC       APB). Also activated by hyperoxia. Acivated by intracellular Zn(2+).
CC       TRPA1 activation may critically depend on the presence of small
CC       intracellular compounds such as polyphosphates (By similarity).
CC       {ECO:0000250|UniProtKB:O75762, ECO:0000269|PubMed:14712238,
CC       ECO:0000269|PubMed:18775987, ECO:0000269|PubMed:21402443}.
CC   -!- SUBUNIT: Homotetramer (By similarity). Interacts with TMEM100 (By
CC       similarity). Interacts with EGLN1 (By similarity). Interacts with the
CC       scorpion wasabi receptor toxin at the same site that electrophiles but
CC       in a non-covalent manner (By similarity).
CC       {ECO:0000250|UniProtKB:O75762, ECO:0000250|UniProtKB:Q8BLA8}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q8BLA8};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:O75762}.
CC   -!- TISSUE SPECIFICITY: Specifically expressed in a subset of nociceptive
CC       neurons. Expressed in dorsal root ganglia.
CC       {ECO:0000269|PubMed:12654248}.
CC   -!- DOMAIN: C-terminal helices from the four subunits associate to form
CC       atypical coiled coil structure; this region is probably involved in
CC       binding the inositol polyphosphates that are required for optimal
CC       channel activity (in vitro). {ECO:0000250|UniProtKB:O75762}.
CC   -!- DOMAIN: The ANK repeat domain consists of a convex stem structure
CC       followed by a crescent-shaped structure that surrounds the protein
CC       core. {ECO:0000250|UniProtKB:O75762}.
CC   -!- PTM: TRPA1 activation by electrophiles occurs though covalent
CC       modification of specific cysteine residues in the N-terminal
CC       cytoplasmic domain (By similarity). {ECO:0000250|UniProtKB:Q8BLA8}.
CC   -!- PTM: Hydroxylation is required for TRPA1 activity inhibition in
CC       normoxia. In hypoxia, the decrease in oxygen concentration diminishes
CC       the activity of the hydroxylase EGLN1, thus relieving TRPA1 from
CC       inhibition and ultimately leading to channel activation.
CC       {ECO:0000250|UniProtKB:O75762}.
CC   -!- PTM: Oxidation of Cys-634 and Cys-859 in hyperoxia may override the
CC       hydroxylase EGLN1-mediated inhibition, causing TRPA1 activation.
CC       {ECO:0000250|UniProtKB:O75762}.
CC   -!- SIMILARITY: Belongs to the transient receptor (TC 1.A.4) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The power behind pain
CC       - Issue 82 of May 2007;
CC       URL="https://web.expasy.org/spotlight/back_issues/082";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY496961; AAS78661.1; -; mRNA.
DR   EMBL; AABR07046729; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_997491.1; NM_207608.1.
DR   AlphaFoldDB; Q6RI86; -.
DR   SMR; Q6RI86; -.
DR   DIP; DIP-61522N; -.
DR   STRING; 10116.ENSRNOP00000009874; -.
DR   BindingDB; Q6RI86; -.
DR   ChEMBL; CHEMBL5160; -.
DR   DrugCentral; Q6RI86; -.
DR   GuidetoPHARMACOLOGY; 485; -.
DR   GlyCosmos; Q6RI86; 2 sites, No reported glycans.
DR   GlyGen; Q6RI86; 2 sites.
DR   PhosphoSitePlus; Q6RI86; -.
DR   PaxDb; 10116-ENSRNOP00000009874; -.
DR   Ensembl; ENSRNOT00000009874.3; ENSRNOP00000009874.2; ENSRNOG00000007354.3.
DR   Ensembl; ENSRNOT00055018742; ENSRNOP00055015102; ENSRNOG00055011060.
DR   Ensembl; ENSRNOT00060002897; ENSRNOP00060001899; ENSRNOG00060001872.
DR   Ensembl; ENSRNOT00065017425; ENSRNOP00065013360; ENSRNOG00065010758.
DR   GeneID; 312896; -.
DR   KEGG; rno:312896; -.
DR   UCSC; RGD:1303284; rat.
DR   AGR; RGD:1303284; -.
DR   CTD; 8989; -.
DR   RGD; 1303284; Trpa1.
DR   eggNOG; KOG0510; Eukaryota.
DR   GeneTree; ENSGT00940000156118; -.
DR   HOGENOM; CLU_006750_0_0_1; -.
DR   InParanoid; Q6RI86; -.
DR   OMA; HWATEKN; -.
DR   OrthoDB; 2910129at2759; -.
DR   PhylomeDB; Q6RI86; -.
DR   TreeFam; TF317264; -.
DR   Reactome; R-RNO-3295583; TRP channels.
DR   PRO; PR:Q6RI86; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   Bgee; ENSRNOG00000007354; Expressed in duodenum and 6 other cell types or tissues.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:RGD.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0032421; C:stereocilium bundle; ISO:RGD.
DR   GO; GO:0005262; F:calcium channel activity; ISO:RGD.
DR   GO; GO:0015267; F:channel activity; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0015278; F:intracellularly gated calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005216; F:monoatomic ion channel activity; ISO:RGD.
DR   GO; GO:1990760; F:osmolarity-sensing monoatomic cation channel activity; IDA:RGD.
DR   GO; GO:0097604; F:temperature-gated cation channel activity; ISS:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:RGD.
DR   GO; GO:0097553; P:calcium ion transmembrane import into cytosol; IDA:RGD.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; ISO:RGD.
DR   GO; GO:0071313; P:cellular response to caffeine; IEP:RGD.
DR   GO; GO:0071244; P:cellular response to carbon dioxide; IDA:RGD.
DR   GO; GO:0070417; P:cellular response to cold; IMP:RGD.
DR   GO; GO:0034605; P:cellular response to heat; IMP:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISO:RGD.
DR   GO; GO:0050968; P:detection of chemical stimulus involved in sensory perception of pain; ISO:RGD.
DR   GO; GO:0050974; P:detection of mechanical stimulus involved in sensory perception; ISO:RGD.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; ISO:RGD.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; ISO:RGD.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:RGD.
DR   GO; GO:1903793; P:positive regulation of monoatomic anion transport; IMP:RGD.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:1903522; P:regulation of blood circulation; IMP:RGD.
DR   GO; GO:0098908; P:regulation of neuronal action potential; IMP:RGD.
DR   GO; GO:0009409; P:response to cold; ISS:UniProtKB.
DR   GO; GO:0042542; P:response to hydrogen peroxide; ISO:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; ISO:RGD.
DR   GO; GO:0048265; P:response to pain; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; ISO:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0050955; P:thermoception; ISO:RGD.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; IMP:RGD.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 4.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR052076; TRP_cation_channel.
DR   PANTHER; PTHR47143; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL PROTEIN PAINLESS; 1.
DR   PANTHER; PTHR47143:SF3; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL PROTEIN PAINLESS; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 5.
DR   Pfam; PF00520; Ion_trans; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 14.
DR   SUPFAM; SSF48403; Ankyrin repeat; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 9.
PE   1: Evidence at protein level;
KW   ANK repeat; Calcium; Calcium channel; Calcium transport; Cell membrane;
KW   Coiled coil; Disulfide bond; Glycoprotein; Hydroxylation; Ion channel;
KW   Ion transport; Membrane; Metal-binding; Oxidation; Reference proteome;
KW   Repeat; Sensory transduction; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..1125
FT                   /note="Transient receptor potential cation channel
FT                   subfamily A member 1"
FT                   /id="PRO_0000215371"
FT   TOPO_DOM        1..721
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TRANSMEM        722..742
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        743..767
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TRANSMEM        768..788
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        789..806
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TRANSMEM        807..827
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        828..832
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TRANSMEM        833..853
FT                   /note="Helical;Name=4"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        854..876
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TRANSMEM        877..897
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        898..904
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   INTRAMEM        905..925
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        926..937
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TRANSMEM        938..959
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   TOPO_DOM        960..1125
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   REPEAT          63..94
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          98..127
FT                   /note="ANK 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          131..161
FT                   /note="ANK 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          165..194
FT                   /note="ANK 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          198..227
FT                   /note="ANK 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          239..268
FT                   /note="ANK 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          272..301
FT                   /note="ANK 7"
FT                   /evidence="ECO:0000255"
FT   REPEAT          309..338
FT                   /note="ANK 8"
FT                   /evidence="ECO:0000255"
FT   REPEAT          342..371
FT                   /note="ANK 9"
FT                   /evidence="ECO:0000255"
FT   REPEAT          413..442
FT                   /note="ANK 10"
FT                   /evidence="ECO:0000255"
FT   REPEAT          446..475
FT                   /note="ANK 11"
FT                   /evidence="ECO:0000255"
FT   REPEAT          482..511
FT                   /note="ANK 12"
FT                   /evidence="ECO:0000255"
FT   REPEAT          514..543
FT                   /note="ANK 13"
FT                   /evidence="ECO:0000255"
FT   REPEAT          548..577
FT                   /note="ANK 14"
FT                   /evidence="ECO:0000255"
FT   COILED          1044..1073
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         415
FT                   /ligand="(E)-cinnamaldehyde"
FT                   /ligand_id="ChEBI:CHEBI:16731"
FT                   /ligand_note="agonist"
FT                   /note="covalent"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BLA8"
FT   BINDING         422
FT                   /ligand="(E)-cinnamaldehyde"
FT                   /ligand_id="ChEBI:CHEBI:16731"
FT                   /ligand_note="agonist"
FT                   /note="covalent"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BLA8"
FT   BINDING         622
FT                   /ligand="(E)-cinnamaldehyde"
FT                   /ligand_id="ChEBI:CHEBI:16731"
FT                   /ligand_note="agonist"
FT                   /note="covalent; Cys highly reactive"
FT                   /evidence="ECO:0000250|UniProtKB:O75762,
FT                   ECO:0000250|UniProtKB:Q8BLA8"
FT   BINDING         642
FT                   /ligand="(E)-cinnamaldehyde"
FT                   /ligand_id="ChEBI:CHEBI:16731"
FT                   /ligand_note="agonist"
FT                   /note="covalent"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         666
FT                   /ligand="(E)-cinnamaldehyde"
FT                   /ligand_id="ChEBI:CHEBI:16731"
FT                   /ligand_note="agonist"
FT                   /note="covalent"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         712
FT                   /ligand="(E)-cinnamaldehyde"
FT                   /ligand_id="ChEBI:CHEBI:16731"
FT                   /ligand_note="agonist"
FT                   /note="covalent"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         791
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         794
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         808
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         811
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   BINDING         1048..1054
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol)"
FT                   /ligand_id="ChEBI:CHEBI:57880"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   SITE            622
FT                   /note="Essential for electrophile activation. Sensor for
FT                   electrophilic agents"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   SITE            623
FT                   /note="Key residue for activation by the scorpion wasabi
FT                   receptor toxin"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   SITE            635
FT                   /note="Important residue for activation by the scorpion
FT                   wasabi receptor toxin"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   SITE            647
FT                   /note="Important residue for activation by the scorpion
FT                   wasabi receptor toxin"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   SITE            918
FT                   /note="Crucial for calcium permeation"
FT                   /evidence="ECO:0000269|PubMed:18775987"
FT   MOD_RES         395
FT                   /note="4-hydroxyproline; transient"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   MOD_RES         634
FT                   /note="Cysteine sulfenic acid (-SOH); transient; in
FT                   hyperoxia"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   MOD_RES         859
FT                   /note="Cysteine sulfenic acid (-SOH); transient; in
FT                   hyperoxia"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   CARBOHYD        749
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        755
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        193..666
FT                   /note="Alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BLA8"
FT   DISULFID        463..666
FT                   /note="Alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BLA8"
FT   DISULFID        609..622
FT                   /note="Alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BLA8"
FT   DISULFID        622..666
FT                   /note="Alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BLA8"
FT   DISULFID        634..859
FT                   /note="Alternate; transient; in hyperoxia; unknown whether
FT                   inter- or intrachain"
FT                   /evidence="ECO:0000250|UniProtKB:O75762"
FT   MUTAGEN         918
FT                   /note="D->A: Ca(2+) permeability is greatly reduced."
FT                   /evidence="ECO:0000269|PubMed:18775987"
FT   MUTAGEN         918
FT                   /note="D->E: Ca(2+) permeability is greatly increased."
FT                   /evidence="ECO:0000269|PubMed:18775987"
FT   CONFLICT        27
FT                   /note="E -> K (in Ref. 1; AAS78661)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1125 AA;  128603 MW;  BAA65992F690E10D CRC64;
     MKRSLRRVLR PEERKEVQGV VYRGVGEDMD CSKESFKVDI EGDMCRLEAF IKNRRKLSKY
     EDENLCLLHH AAAEGQVELM QLIINGSSCE ALNVMDDYGN TPLHWAAEKN QVESVKFLLS
     QGANPNLRNR NMMAPLHIAV QGMYNEVIKV LTEHKATNIN LEGENGNTAL MSTCAKDNSE
     ALQILLEKGA KLCKSNKWGD YPVHQAAFSG AKRCMELILA YGEKTGYSRE AHINFVNHKK
     ASPLHLAVQS GDLDMIKMCL DSGAHIDMME NAKCMALHFA ATQGATDIVK LMISSYTGSS
     DIVNAVDGNQ ETLLHRASLF DHHDLADYLI SVGADINSTD SEGRSPLILA TASASWNIVN
     LLLSKGAKVD IKDHLGRNFL HLTVQQPYGL RNLRPEFLQM QHIKELVMDE DNDGCTPLHY
     ACRQGAPVSV NNLLRFNVSV HSKSKDKKSP LHFAASYGRI NTCQRLLQDI SDTRLLNEGD
     LHGMTPLHLA AKNGHDKVVQ LLLKKGALFL SDHNGWTALH HASMGGYTQT MKVILDTNLK
     CTDRLDEEGN TALHFAAREG HAKAVAMLLS YNADILLNKK QASFLHIALH NKRKEVVLTT
     IRSKRWDECL QVFTHDSPSN RCPIMEMVEY LPECMKVLLD FCMIPSTEDK SCQDYHIEYN
     FKYLQCPLSM TKKVTPTQDV IYEPLTILNV MVQHNRIELL NHPVCREYLL MKWCAYGFRA
     HMMNLGSYCL GLIPMTLLVV KIQPGMAFNS TGIINETIST HEERINTLNS FPLKICMILV
     FLSSIFGYCK EVVQIFQQKR NYFLDYNNAL EWVIYTTSMI FVLPLFLDIP AYMQWQCGAI
     AIFFYWMNFL LYLQRFENCG IFIVMLEVIF KTLLRSTGVF IFLLLAFGLS FYVLLNFQDA
     FSTPLLSLIQ TFSMMLGDIN YRDAFLEPLF RNELAYPVLT FGQLIAFTMF VPIVLMNLLI
     GLAVGDIAEV QKHASLKRIA MQVELHTNLE KKLPFWYLRK VDQRSTIVYP NRPRHGRMLR
     FFHYFLSMQE TRQEAPNIDT CLEMEILKQK YRLKDLTSLL EKQHELIKLI IQKMEIISET
     EDEDNHCSFQ DRFKKERLEQ MHSKWNFVLN AVKTKTHCSI SHPDI
//
